Ultime notizie per Beyond Air (NASDAQ:XAIR) Azioni

Beyond Air

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Konskie,,Poland,-,May,27,,2024:,Korn,Ferry,Company,Logo

Pre-Market Outlook

BTDR

ESEA

XAIR

Un&#39;analisi dei titoli che potrebbero influenzare la giornata di trading. Non perdere le ultime tendenze e i segnali chiave.

Futures in rialzo: i titoli da monitorare in questo mercoledì

Beyond Air Inc

JP Morgan analyst Jeremy Metz maintains First Quantum Minerals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FM#TSX">FM</a>) with a Neutral and raises the price target from C$17 to C$18.

News

Price Target

Analyst Ratings

TSX:FM

JP Morgan Maintains Neutral on First Quantum Minerals, Raises Price Target to C$18

Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Astellas Pharma Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ALPMF#OTC">ALPMF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ALPMY#OTC">ALPMY</a>) on Thursday <a href="https://newsroom.astellas.us/2025-07-10-XTANDI-R-Plus-Leuprolide-Significantly-Improves-Survival-Outcomes-in-Men-with-Non-Metastatic-Hormone-Sensitive-Prostate-Cancer-with-High-Risk-Biochemical-Recurrence?_gl=1&#x2A;io3uax&#x2A;_gcl_au&#x2A;MTgxMjM4ODIyNy4xNzUwMDg5NzEzLjE2ODQwOTM5MDUuMTc1MDk3NjkxOC4xNzUwOTc2OTE5&#x2A;_ga&#x2A;MTMzODE1NTQwNC4xNzM0MzgyMDk4&#x2A;_ga_MBTGG7KX5Y&#x2A;czE3NTIxNzIzMjMkbzUxOSRnMSR0MTc1MjE3MjkyMSRqNTQkbDAkaDYzMTEyOTQ4MA..">released</a> topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as a monotherapy, in men with non-metastatic hormone-sensitive prostate cancer with biochemical recurrence (BCR) <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">at high risk for metastasis</a>.
For patients treated with Xtandi plus leuprolide versus placebo plus leuprolide, EMBARK met the key secondary endpoint with a statistically significant and clinically <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46338864/xtandi-plus-leuprolide-significantly-improves-survival-outcomes-in-men-with-non-metastatic-hormone" rel="noreferrer noopener">meaningful improvement in OS</a>.
There was a favorable trend in results towards improved OS for patients treated with Xtandi monotherapy versus placebo plus leuprolide; however, the difference did not reach statistical significance.
Also Read: <a href="https://www.benzinga.com/25/02/43737281/pfizers-talzennaxtandi-combo-improves-survival-outcomes-in-metastatic-castration-resistant-prostate-cancer" target="_blank" rel="noreferrer noopener">Pfizer&#8217;s Talzenna/Xtandi Combo Improves Survival Outcomes In Metastatic Castration-Resistant Prostate Cancer</a>
No new safety signals were observed in the analysis, and the safety results were consistent with Xtandi&#8217;s demonstrated safety profile.
In the EMBARK study, patients were randomized to one of three study arms: Xtandi plus leuprolide, placebo plus leuprolide or XTANDI monotherapy.
An initial analysis was previously reported in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nejm.org%2Fdoi%2F10.1056%2FNEJMoa2303974%3Furl_ver%3DZ39.88-2003%26rfr_id%3Dori%3Arid%3Acrossref.org%26rfr_dat%3Dcr_pub%2520%25200pubmed&amp;esheet=54287549&amp;newsitemid=20250710409204&amp;lan=en-US&amp;anchor=The+New+England+Journal+of+Medicine&amp;index=1&amp;md5=878c841b90a3bbee8da8c9e6a73ed146" target="_blank" rel="noreferrer noopener">The New England Journal of Medicine</a> in 2023, demonstrating that the study met its primary endpoint with a statistically significant and clinically meaningful improvement in MFS for patients treated with Xtandi plus leuprolide versus placebo plus leuprolide.
The most common adverse events (occurring in ≥10% of patients) in the combination group and the leuprolide-alone group were hot flashes and fatigue. The most common adverse events in the monotherapy group were gynecomastia, hot flashes, and fatigue.
Xtandi is approved in over 80 countries, including the U.S., the EU and Japan.
Detailed OS results from EMBARK will be presented at a future medical meeting.
In May, Astellas and Pfizer <a href="https://www.pfizer.com/news/press-release/press-release-detail/astellas-and-pfizers-xtanditm-enzalutamide-shows-long-term" target="_blank" rel="noreferrer noopener">announced</a> longer-term follow-up results from an open-label extension of the Phase 3 ARCHES study, reporting a five-year follow-up of overall survival (OS) benefits and a 30% reduction in the risk of death in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with Xtandi plus androgen deprivation therapy (ADT) compared to placebo plus ADT.
In March, the U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Pluvicto for <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44544720/fda-oks-novartis-prostate-cancer-treatment-triples-eligible-patient-pool" rel="noreferrer noopener">prostate cancer patients</a>.
The expanded indication, which approximately triples the number of patients eligible to receive Pluvicto, is based on the Phase 3 PSMAfore trial results.
Novartis is investigating Pluvicto in earlier stages of the disease, including metastatic hormone-sensitive prostate cancer and oligometastatic prostate cancer.
PFE, ALPMY Price Actions: Pfizer stock is up 1.13% at $25.85; Astellas is down 0.64% at $9.40 at publication on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46347324/musk-says-grok-coming-to-teslas-by-next-week-evs-getting-the-smartest-ai-in-the-world" target="_blank" rel="noreferrer noopener">Musk Says Grok Coming To Teslas By Next Week: EVs Getting &#8216;The Smartest AI In The World&#8217;</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

General

ALPMF

ALPMY

Pfize, Astellas Report Xtandi Survival Win In Prostate Cancer Study

JP Morgan analyst Anupam Rama maintains Cogent Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) with a Overweight and raises the price target from $25 to $29.

COGT

JP Morgan Maintains Overweight on Cogent Biosciences, Raises Price Target to $29

WIIM

Carlyle Group shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and raised its price target from $44 to $65.

STMicroelectronics shares are trading higher after the company signed a license agreement with Metalenz.

JP Morgan analyst Tami Zakaria maintains Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) with a Overweight and raises the price target from $395 to $475.

JP Morgan Maintains Overweight on Caterpillar, Raises Price Target to $475

<a href="https://www.eventbrite.co.uk/e/mni-webcast-with-mary-c-daly-tickets-1367084138459" title="https://www.eventbrite.co.uk/e/mni-webcast-with-mary-c-daly-tickets-1367084138459">https://www.eventbrite.co.uk/e/mni-webcast-with-mary-c-daly-tickets-1367084138459</a>

Macro Economic Events

Economics

Federal Reserve

Fed's Daly Says To Cut Rates, Needs A Continuation Of Current Data Trends; Labor Market Supply And Demand Is Roughly In Balance; Economic Fundamentals Support A Move Toward Lower Rates At Some Point; Real Labor Market Weakening Could Drive Rate Cut, But Inflation Issues Could Lean Other Way; Fed Should Always Have An Open Mind About Changing Rates

JP Morgan analyst Tami Zakaria maintains AGCO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>) with a Overweight and raises the price target from $117 to $130.

AGCO

JP Morgan Maintains Overweight on AGCO, Raises Price Target to $130

JP Morgan analyst Patrick Jones downgrades Lundin Mining (TSX:<a class="ticker" href="https://www.benzinga.com/stock/LUN#TSX">LUN</a>) from Overweight to Neutral and raises the price target from C$15.3 to C$15.6.

Downgrades

TSX:LUN

JP Morgan Downgrades Lundin Mining to Neutral, Raises Price Target to C$15.6

Valero Energy shares are trading higher after Piper Sandler maintained an Overweight rating and raised its price target to $160.

Fed's Daly Says I See Two Two Cuts As A Likely Outcome For Fed; There's A Large Amount Of Uncertainty Around Policy Outlook

Fed's Daly Says Labor Market Is Cooling And Growth Is Moderating, But Data Is Not Getting Meaningfully Weaker; Doesn't Expect Very Persistent Inflation Impact From Tariffs; It's Possible Tariffs Don't Create A Large Increase In Prices; It's Time To Think About Adjusting The Interest Rate

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), on Thursday, announced an exclusive licensing agreement for IGI&#8217;s lead investigational asset, ISB 2001, developed using IGI&#8217;s proprietary BEAT protein platform, for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">oncology and autoimmune diseases</a>.
&#8220;Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper, more durable responses by engaging multiple targets simultaneously,&#8221; said Roopal Thakkar, AbbVie executive vice-president of research and development, and chief scientific officer.
AbbVie will receive exclusive rights to develop, manufacture and commercialize ISB 2001 across North America, Europe, <a href="https://www.benzinga.com/pressreleases/25/07/g46339734/ichnos-glenmark-innovation-igi-and-abbvie-announce-exclusive-global-licensing-agreement-for-isb-20" target="_blank" rel="noreferrer noopener">Japan and Greater China</a>.
IGI will receive an upfront payment of $700 million and is eligible to receive up to $1.225 billion in development, regulatory, and commercial milestone payments, along with tiered, double-digit royalties on net sales.
ISB&nbsp;2001 is a first-in-class trispecific T-cell engager that targets BCMA and CD38 on myeloma cells and CD3 on T cells. It is currently in Phase&nbsp;1 for relapsed/refractory multiple myeloma.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/46001795/abbvies-migraine-drug-achieves-superiority-in-preventing-headaches-compared-to-generic-treatment-in-head-to-head-trial" rel="noreferrer noopener">AbbVie&#8217;s Migraine Drug Outperforms Generic Treatment In Head-To-Head Trial</a>
Recently presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting as a Rapid Oral Presentation, data from 35 patients demonstrated a sustained overall response rate (ORR) of 79% and a high complete/stringent complete response (CR/sCR) rate of 30% at active doses ≥ 50 µg/kg in a heavily pretreated population of relapsed/refractory myeloma patients, with a favorable safety profile.
U.S. Food &amp; Drug Administration granted ISB&nbsp;2001 Orphan Drug Designation in July 2023 and Fast Track Designation for relapsed/refractory myeloma patients in May 2025.&nbsp;
What&#8217;s Going On With Other Companies: According to a July media report, AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) was reportedly in talks with Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) about a partnership <a href="https://www.benzinga.com/news/contracts/25/07/46249640/astrazeneca-in-15b-talks-for-drug-that-could-upend-lung-cancer-treatment" target="_blank" rel="noreferrer noopener">worth up to $15 billion.</a>
The deal would give AstraZeneca the rights to a lung cancer drug called ivonescimab.
In June, BioNTech SE  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) and Bristol Myers Squibb &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) entered into a co-development and <a href="https://www.benzinga.com/news/health-care/25/06/45723383/bristol-myers-inks-11-billion-licensing-pact-with-biontech-for-bispecific-cancer-drug" target="_blank" rel="noreferrer noopener">co-commercialization agreement</a>.
The pact focuses on BioNTech's investigational bispecific antibody BNT327 across numerous <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">solid tumor types</a>.
Bristol Myers Squibb will pay BioNTech $1.5 billion upfront and $2 billion in non-contingent anniversary payments through 2028. In addition, BioNTech will be eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones.
ABBV Price Action: AbbVie stock is up 2.63% at $195.63 at publication on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/07/46344208/ultragenyx-mereo-shares-dive-as-brittle-bone-disease-drug-misses-early-win" target="_blank" rel="noreferrer noopener">Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win</a></li>
</ul>

Contracts

Movers

Trading Ideas

ABBV

BNTX

SMMT

Why Is AbbVie Stock Trading Higher On Thursday?

DLTR

Dollar Tree shares are trading higher after the company announced a $2.5 billion share repurchase authorization.

Fed's Daly Says The Economy Is In A Good Place, Growth And Jobs Solid, Inflation Easing; Fed Has Ability To Restore Price Stability Gently Given State Of Economy; Monetary Policy Is Still Restrictive

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher amid a decline in initial jobless claims.

The evolving landscape of high-performance computing (HPC) is reshaping how investors view traditional <a href="https://www.benzinga.com/topic/bitcoin-mining">bitcoin mining companies</a>, as evidenced by the recent downgrade of Core Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>)
Needham analyst John Todaro downgraded Core Scientific from Buy to Hold. The analyst has not given a price forecast following the downgrade compared to his earlier forecast of $18.
Todaro highlights that the company&#8217;s investment case rests largely on the expanding opportunity in high-performance computing and AI infrastructure.
He notes that among bitcoin miners, Core Scientific stands out as an early mover in what's expected to become a rapidly growing, high-demand space for data center capacity.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/07/46306575/why-coreweaves-9-billion-deal-isnt-about-chips" rel="noreferrer noopener">Why CoreWeave&#8217;s $9 Billion Deal Isn&#8217;t About Chips</a>
With the increasing need for computing power to support AI, Bitcoin miners are seen as well-positioned to meet this demand, especially given current constraints on rack space and power.
Todaro notes that CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) announced all-stock acquisition of Core Scientific, expected to close in the fourth quarter of 2025, led to a 22% drop in Core Scientific shares—likely due to the stock-only nature of the deal, a lower-than-anticipated valuation, and limited arbitrage potential given CoreWeave&#8217;s borrowing constraints.
As a result, Todaro downgrades Core Scientific, aligning with his CoreWeave downgrade.
He sees the merger as strategically beneficial, adding 150-200MW of IT capacity for CoreWeave, and considers a competing offer from a major hyperscaler unlikely due to existing tenant ties.
While there&#8217;s a chance that Core Scientific shareholders could vote against the deal, insider and board support—representing approximately 14% of shares—makes approval more likely.
Apart from this, Core Scientific has made notable progress in HPC, including a recent multi-year agreement with CoreWeave.
The company now holds contracts for roughly 385 megawatts of HPC co-location capacity, representing over $500 million in potential annual revenue.
Todaro estimates Core Scientific will have 271 megawatts operational by the end of calendar year 2025 and 383 megawatts by the end of 2026, positioning it as one of the first, if not the first, bitcoin miners to bring a 100+ megawatt HPC facility online.
Furthermore, Core Scientific&#8217;s site portfolio is viewed as particularly suited for HPC due to proximity to metro areas and the presence of pre-installed fiber.
These attributes, Todaro adds, reduce the capital costs associated with converting bitcoin mining infrastructure to HPC, especially when compared to competitors operating in West Texas. Given Core Scientific's head start in the HPC space, its cost advantages, and the strong CoreWeave deal, he believes the stock warrants a 15x EV/EBITDA multiple on discounted 2026 projections.
Price Action: CRWV shares are trading lower by 5.19% to $145.17 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46350022/amazon-prime-day-1-sales-roar-to-7-9-billion-shoppers-slam-website-with-traffic-up-50" target="_blank" rel="noreferrer noopener">Amazon Prime Day 1 Sales Roar To $7.9 Billion, Shoppers Slam Website With Traffic Up 50%+</a></li>
</ul>
Photo: Shutterstock

Equities

Markets

Core Scientific, Inc. - Class A Common Stock

CORZ

CRWV

Core Scientific Downgraded Over Concerns On Acquisition Deal

Scotiabank analyst Konark Gupta maintains Canadian Pacific Kansas (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CP#TSX">CP</a>) with a Sector Outperform and raises the price target from C$115 to C$120.

TSX:CP

Scotiabank Maintains Sector Outperform on Canadian Pacific Kansas, Raises Price Target to C$120

Scotiabank analyst Konark Gupta maintains Cargojet (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CJT#TSX">CJT</a>) with a Sector Outperform and lowers the price target from C$139 to C$138.

TSX:CJT

Scotiabank Maintains Sector Outperform on Cargojet, Lowers Price Target to C$138

<a href="https://www.bloomberg.com/news/articles/2025-07-10/citadel-securities-buys-morgan-stanley-s-options-market-maker?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-10/citadel-securities-buys-morgan-stanley-s-options-market-maker?embedded-checkout=true</a>

'Citadel Securities Buys Morgan Stanley's Options Market Maker'- Bloomberg

Financing

Press Releases

NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site

NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

Management

NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

Legal

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections  Using gaseous Nitric Oxide (gNO)

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast

Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH

Earnings

Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Comments

Beyond Air

Notizie

Ultime notizie per Beyond Air (NASDAQ:XAIR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO